

November 15, 2019

Novartis Pharma AG  
CH-4002, Basel, Switzerland

Reference: EudraCT 2013-004139-62/ Novartis Protocol ID CRAD001JES13

A pilot open-label, phase II, single-arm study to evaluate the association of biomarkers of hormonal resistance and the mTOR pathway with the clinical efficacy of Everolimus plus letrozole in the first line treatment of postmenopausal women with hormone positive metastatic or locally advanced breast cancer

Trial CRAD001JES13 was cancelled with no patient enrollment and as such, no results will be reported.

Due to a flaw in the EudraCT system, the Global End of Trial date in the system only was changed to July 1, 2012 to allow upload of this letter to notify the public that this trial was cancelled and no patients were enrolled.